Efficacy, pharmacokinetics, and safety of adalimumab in pediatric patients with juvenile idiopathic arthritis in Japan
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1434-9949
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Efficacy, pharmacokinetics, and safety of adalimumab in pediatric patients with juvenile idiopathic arthritis in Japan ; volume:31 ; number:12 ; day:2 ; month:10 ; year:2012 ; pages:1713-1721 ; date:12.2012
Clinical rheumatology ; 31, Heft 12 (2.10.2012), 1713-1721, 12.2012
- Creator
-
Imagawa, Tomoyuki
Takei, Syuji
Umebayashi, Hiroaki
Yamaguchi, Kenichi
Itoh, Yasuhiko
Kawai, Toshinao
Iwata, Naomi
Murata, Takuji
Okafuji, Ikuo
Miyoshi, Mari
Onoe, Yasuhiro
Kawano, Yoshifumi
Kinjo, Noriko
Mori, Masaaki
Mozaffarian, Neelufar
Kupper, Hartmut
Santra, Sourav
Patel, Gina
Kawai, Shinichi
Yokota, Shumpei
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s10067-012-2082-5
- URN
-
urn:nbn:de:101:1-2019062723011661884113
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
14.08.2025, 10:54 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Imagawa, Tomoyuki
- Takei, Syuji
- Umebayashi, Hiroaki
- Yamaguchi, Kenichi
- Itoh, Yasuhiko
- Kawai, Toshinao
- Iwata, Naomi
- Murata, Takuji
- Okafuji, Ikuo
- Miyoshi, Mari
- Onoe, Yasuhiro
- Kawano, Yoshifumi
- Kinjo, Noriko
- Mori, Masaaki
- Mozaffarian, Neelufar
- Kupper, Hartmut
- Santra, Sourav
- Patel, Gina
- Kawai, Shinichi
- Yokota, Shumpei
- SpringerLink (Online service)
Other Objects (12)
Population Pharmacokinetics of Adalimumab in Juvenile Idiopathic Arthritis Patients: A Retrospective Cohort Study Using Clinical Care Data
Golimumab in juvenile idiopathic arthritis-associated uveitis unresponsive to Adalimumab
Safety, effectiveness, and pharmacokinetics of adalimumab in children with polyarticular juvenile idiopathic arthritis aged 2 to 4 years
Adalimumab-induced manic episode in an adolescent with juvenile idiopathic arthritis
Discontinuing adalimumab in patients with controlled juvenile idiopathic arthritis-associated uveitis (ADJUST—Adalimumab in Juvenile Idiopathic Arthritis-associated Uveitis Stopping Trial): study protocol for a randomised controlled trial
Adalimumab treatment in Juvenile Idiopathic Arthritis (JIA) patients with special focus on Uveitis
Administration of routine preventative vaccinations in children with polyarticular juvenile idiopathic arthritis receiving adalimumab
Efficacy of adalimumab in refractory juvenile idiopathic arthritis related uveitis: report of 6 cases
Juvenile idiopathische Arthritis – Adalimumab – sicher und effizient
Adalimumab Effectively Decreases Inflammation Downstream of TNFα Signaling in Synoviocytes from Extended Oligoarticular Juvenile Idiopathic Arthritis
Same but different? A thematic analysis on adalimumab biosimilar switching among patients with juvenile idiopathic arthritis
Juvenile idiopathische Arthritis – Langzeitsicherheit von Etanercept und Adalimumab
Population Pharmacokinetics of Adalimumab in Juvenile Idiopathic Arthritis Patients: A Retrospective Cohort Study Using Clinical Care Data
Golimumab in juvenile idiopathic arthritis-associated uveitis unresponsive to Adalimumab
Safety, effectiveness, and pharmacokinetics of adalimumab in children with polyarticular juvenile idiopathic arthritis aged 2 to 4 years
Adalimumab-induced manic episode in an adolescent with juvenile idiopathic arthritis
Discontinuing adalimumab in patients with controlled juvenile idiopathic arthritis-associated uveitis (ADJUST—Adalimumab in Juvenile Idiopathic Arthritis-associated Uveitis Stopping Trial): study protocol for a randomised controlled trial
Adalimumab treatment in Juvenile Idiopathic Arthritis (JIA) patients with special focus on Uveitis
Administration of routine preventative vaccinations in children with polyarticular juvenile idiopathic arthritis receiving adalimumab
Efficacy of adalimumab in refractory juvenile idiopathic arthritis related uveitis: report of 6 cases
Juvenile idiopathische Arthritis – Adalimumab – sicher und effizient
Adalimumab Effectively Decreases Inflammation Downstream of TNFα Signaling in Synoviocytes from Extended Oligoarticular Juvenile Idiopathic Arthritis
Same but different? A thematic analysis on adalimumab biosimilar switching among patients with juvenile idiopathic arthritis
Juvenile idiopathische Arthritis – Langzeitsicherheit von Etanercept und Adalimumab
Population Pharmacokinetics of Adalimumab in Juvenile Idiopathic Arthritis Patients: A Retrospective Cohort Study Using Clinical Care Data
Golimumab in juvenile idiopathic arthritis-associated uveitis unresponsive to Adalimumab
Safety, effectiveness, and pharmacokinetics of adalimumab in children with polyarticular juvenile idiopathic arthritis aged 2 to 4 years
Adalimumab-induced manic episode in an adolescent with juvenile idiopathic arthritis
Discontinuing adalimumab in patients with controlled juvenile idiopathic arthritis-associated uveitis (ADJUST—Adalimumab in Juvenile Idiopathic Arthritis-associated Uveitis Stopping Trial): study protocol for a randomised controlled trial
Adalimumab treatment in Juvenile Idiopathic Arthritis (JIA) patients with special focus on Uveitis
Administration of routine preventative vaccinations in children with polyarticular juvenile idiopathic arthritis receiving adalimumab
Efficacy of adalimumab in refractory juvenile idiopathic arthritis related uveitis: report of 6 cases
Juvenile idiopathische Arthritis – Adalimumab – sicher und effizient
Adalimumab Effectively Decreases Inflammation Downstream of TNFα Signaling in Synoviocytes from Extended Oligoarticular Juvenile Idiopathic Arthritis
Same but different? A thematic analysis on adalimumab biosimilar switching among patients with juvenile idiopathic arthritis